Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Cyclophosphamide (Primary) ; Interleukin-2 (Primary) ; Ipilimumab (Primary) ; T cell replacement therapy (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
- 11 Sep 2017 Planned End Date changed from 1 Dec 2021 to 1 Sep 2021.
- 11 Sep 2017 Planned primary completion date changed from 1 Dec 2021 to 1 Sep 2021.
- 11 Sep 2017 Status changed from not yet recruiting to recruiting.